Introduction
TNF-related apoptosis-inducing ligand (TRAIL, also called Apo2L) belongs to a family of structurally related molecules, which also includes TNF, Fas ligand (FasL), and APO3 ligand. These ligands are expressed as type II membrane proteins that are cleaved into soluble, active forms and which bind to members of the TNF receptor super-family. Ligand-mediated receptor activation triggers a cascade of events that begins with death receptor (DR) oligomerization and the close association of their cytoplasmic death domains (DDs). This is followed by DD-associated interaction with adapter molecules and cellular proteases critical to DRinduced apoptosis, including the initiator caspase, caspase 8 and its associated eector caspases, caspases 3 and 7 (reviewed in Ashkenazi and Dixit, 1998) . In addition to activating caspase 8, TRAIL-induced apoptosis is also associated with the cleavage of Bid and the loss of mitochondrial potential (Belka et al., 2001) . TRAIL induces apoptosis by binding to the TNF receptor super-family members DR4 (also called TRAIL-R1) and DR5 (also called Apo2, TRAIL-R2, TRACK2 or KILLER). TRAIL can also bind to the receptors DcR-1 (for Decoy Receptor 1) and DcR-2 that do not transmit apoptotic signals and can prevent the induction of apoptosis in TRAIL-treated cells.
Many cancer chemotherapeutic drugs in clinical use induce apoptosis in sensitive cells suggesting that death-receptor ligands might prove useful as cancer therapeutic agents. Unfortunately, the apoptosis-inducing ligands FasL and TNF are also toxic to nontransformed cells (Nagata, 1997) . TRAIL induces apoptosis in a variety of transformed cells (Wiley et al., 1995; Pitti et al., 1996) , including cells derived from lung, breast, colon, kidney, brain and skin cancers (Ashkenazi et al., 1999) and is eective at reducing mammary adenocarcinoma growth in mice (Walczak et al., 1999) . Although normal cultured hepatocytes do show some sensitivity to TRAIL-induced killing (Jo et al., 2000) , this toxicity can be overcome by simultaneous exposure to the caspase inhibitor, Z-LEHD-fmk (Ozoren et al., 2000) .
TRAIL kills cancer cells derived from a variety of human cancers of diverse type. However, cancer cells of all types appear to dier in their sensitivity to TRAIL-induced apoptosis (Keane et al., 1999; Zhang et al., 1999) . Understanding the basis of TRAIL sensitivity is thus crucial in designing TRAIL-based cancer therapeutic strategies. TRAIL induced apopto-sis is dependent, in part, on the surface expression of its receptors (Zhang et al., 1999) and agents which increase the cell surface expression of DR4 and DR5 enhance TRAIL-induced killing in some epithelialderived tumor cells . Alteration in receptor expression, however, does not fully explain TRAIL sensitivity (Keane et al., 1999; Zhang et al., 1999; Cuello et al., 2001) .
Reovirus infection induces apoptosis in cultured cells in vitro (Tyler et al., 1985 (Tyler et al., , 1995 (Tyler et al., , 1996 . Apoptosis occurs through a p53-independent mechanism that involves cellular proteases including caspases and calpains (DeBiasi et al., 1999) . Reovirus-induced apoptosis in HEK293 cells is mediated by TRAIL and is inhibited by anti-TRAIL antibodies or by soluble forms of DR4 and DR5 . Reovirus infection results in the release of TRAIL from infected HEK293 cells and reovirus sensitizes these cells to TRAIL-induced killing . In neonatal mice, reovirus also induces apoptosis in infected tissues in vivo (Oberhaus et al., 1997 (Oberhaus et al., , 1998 DeBiasi et al., 2001) . However, reovirus infection is not associated with signi®cant disease in adult mice or in humans. Reovirus infection may therefore provide a useful model system for investigations of TRAIL-induced apoptosis in cancer cells. A better understanding of how reovirus infection sensitizes cancer cells to TRAIL-induced cell death may suggest novel mechanisms for increasing the ecacy of TRAIL as a cancer therapeutic agent.
Reovirus has previously been shown to induce killing of human glioblastoma cells in vitro as well as inducing regression of transplanted tumors in mice, although the mechanism for reovirus-induced`oncolysis' has not been fully identi®ed Strong et al., 1998) . We now show that reovirus kills cancer cells by apoptosis and that this apoptosis is both mediated by TRAIL and is associated with the release of TRAIL from infected cells. We further show that reovirus speci®cally sensitizes cancer cell lines to TRAILinduced apoptosis and that this sensitization requires the activation of caspase 8 and is associated with increased activity of eector caspases.
Results

Reovirus and TRAIL induce similar amounts of apoptosis in human cancer cells
It has been reported that reovirus can infect and kill cancer cells Strong et al., 1998) . Our previous work in tissue culture has shown that reovirusinduced killing of many types of non-cancerous cells (Tyler et al., 1985 (Tyler et al., , 1995 (Tyler et al., , 1996 and of cells derived from a human cervical carcinoma (HeLa cells) is due to apoptosis. We therefore wished to determine whether reovirus induced killing of other cancer cell lines was due to apoptosis. Cell lines derived from two dierent human lung (A157 and H549) and breast cancers (MDA231 and ZR75-1) were infected with reovirus (multiplicity of infection, MOI 100) and were harvested and assayed for apoptosis at 48 h post infection. We ®rst assayed apoptosis by determination of the percentage of cells with apoptotic nuclear morphology ( Figure 1A ). The speci®city of this assay for the detection of apoptotic nuclear morphology in reovirus-infected cells has been previously established by our laboratory using DNA laddering techniques and electron microscopy (Tyler et al., 1995) . HeLa cells, which have previously been shown to be susceptible to both reovirus-infection and reovirus-induced apoptosis (Connolly et al., 2000) , were used as positive controls. Reovirus induced signi®cant (P50.05) apoptosis in all of the cancer cell lines tested, but with dierent degrees of eciency. HeLa, A549 and MDA231 cells were the Figure 1 Reovirus induces apoptosis in human tumor cell lines. (A) Cell lines derived from human cervical (HeLa), lung (H157 and A549) and breast (MDA231 and ZR75-1) cancers were infected with reovirus (MOI 100) and were harvested and assayed for apoptosis at 48 h post infection. In a parallel experiment cells were treated with TRAIL (200 ng/ml). The graph shows the mean per cent apoptosis in reovirus (black bars), mock-infected (clear bars) and TRAIL-treated (shaded bars) cancer cells from at least three separate experiments. Error bars represent standard errors of the mean. (B) Caspase 3 activation in reovirus (MOI 100) compared to mock-infected cancer cell lines, at 24 h post infection, as determined by¯uorogenic substrate assay. The graph shows the mean fold-increase in¯uorescence from at least three separate experiments. Error bars represent standard errors of the mean. (C) One step growth curves of reovirus in human cancer cell lines used. Cells were infected with reovirus and were harvested and assayed for growth at 24 and 48 h post infection. The graph shows Log 10 virus yield over time most susceptible to reovirus-induced apoptosis whereas H157 and ZR75-1 cells showed the least susceptibility. These dierences were not caused by dierences in viral growth since one-step growth curves indicated that reovirus grows eciently and equivalently in all the cell lines ( Figure 1C ).
The sensitivity of cells to reovirus-induced apoptosis was compared to their sensitivity to TRAIL-induced apoptosis. Cells were treated with 200 ng/ml TRAIL and assayed for apoptosis after 24 h. All but one (ZR75-1) of the cell lines tested demonstrated signi®cant sensitivity (P50.05) to TRAIL induced apoptosis ( Figure 1A) . A signi®cant correlation was shown between the sensitivity of these cancer lines to reovirus-induced and TRAIL-induced apoptosis (Pearson linear correlation test: correlation coecient (R)=0.9154, coecient of determination (R sq.)=0.8380, P value (2-tailed) 0.0291).
To con®rm that reovirus-induced killing of cancer cells was due to apoptosis we investigated the activity of the apoptosis-speci®c eector caspase, caspase 3, in reovirus-infected cells. Reovirus infection induced a twofold or more activation of caspase 3 in all of the cell lines tested except for ZR75-1 cells. The smaller increase in caspase 3-activation (1.3-fold), seen in ZR75-1 cells corresponds to the low level of apoptosis induced in these cells following reovirus infection ( Figure 1B ).
Reovirus induced apoptosis is mediated by TRAIL
Reovirus induced apoptosis of HEK293 and L929 cells requires the binding of TRAIL to the apoptosisinducing cell surface receptors DR4 and DR5 . Soluble TRAIL receptors (Fc:DR4 and Fc:DR5), but not soluble TNF receptor (Fc:TNFR), speci®cally inhibit TRAIL-induced apoptosis by binding TRAIL and preventing its interaction with functional cell surface DR4 and DR5 . We wished to determine whether reovirusinduced apoptosis of cancer cell lines was also mediated by TRAIL. Human lung, breast and cervical cancer cell lines were infected with reovirus (MOI 50), in the presence or absence of soluble TRAIL receptor (Fc:DR5) or a soluble control receptor (Fc:TNFR), and assayed for apoptosis 48 h following infection with reovirus. Reovirus-induced apoptosis in all of the cancer cell lines, except ZR75-1, was signi®cantly inhibited (P50.05), by treatment with Fc:DR5, but not by Fc:TNFR, indicating that apoptosis in these cells is mediated by TRAIL (Figure 2A ). In the case of ZR75-1 cells, the low basal level of reovirus-induced apoptosis may have precluded the determination of a signi®cant level of inhibition.
To further demonstrate the involvement of TRAIL in reovirus-induced apoptosis we next showed that reovirus-induced apoptosis could be inhibited in a cell line that stably over-expresses the anti-apoptotic TRAIL receptor, DcR-1. MDA-231 cells were transfected with a vector expressing DcR-1 and enhanced cell surface expression of DcR-1 was determined by¯o w cytometry (data not shown). These cells were then infected with reovirus (MOI 100) and assayed for apoptosis after 48 h ( Figure 2B ). Over-expression of DcR-1 signi®cantly (P50.01) inhibited reovirus-induced apoptosis in MDA-231 cells, when compared to MDA-231 control cells transfected with empty vector, again indicating that TRAIL plays a key role in reovirus-induced apoptosis. . After a further 24 h the indicator cells were assayed for apoptosis. Empty bars represent supernatants from mock infected cells, black bars represent supernatants from reovirus infected cells, grey bars represent supernatants from reovirus infected cells that were treated with Fc:DR5 to determine that the apoptosis seen in the indicator cell line was TRAILspeci®c and shaded bars represent supernatants from reovirus infected cells that were treated with anti-reovirus antibody to ensure that apoptosis in the indicator cell line was not due to any reovirus present in the transferred supernatant. The graphs (A, B and C) show per cent apoptosis from three separate experiments. Error bars represent standard errors of the mean TRAIL is released from reovirus infected cancer cells TRAIL is normally expressed as a type II membrane protein that is cleaved into a soluble form. We have previously shown that TRAIL is released from reovirus-infected HEK293 cells . We next investigated whether TRAIL was released from reovirus-infected cancer cells into the supernatant. Twenty-four hours following infection of cancer cells with reovirus the supernatant was collected and transferred onto a TRAIL-sensitive indicator cell line (HeLa). After a further 24 h the indicator cells were assayed for apoptosis. Signi®cant apoptosis (P50.05) was induced in the indicator cell line following treatment with supernatant collected from reovirus-infected, but not from mock-infected Hela, H157, A549 and MDA231 cells ( Figure 2C ). This apoptosis was blocked by soluble DR5 (Fc:DR5) indicating that the apoptosis seen in the indicator cells following supernatant transfer from reovirus-infected cancer cells was speci®c to TRAIL. Supernatant from reovirus-infected ZR75-1 cells did not induce signi®-cant apoptosis in the indicator cell line. A neutralizing polyclonal anti-reovirus antisera, that we have previously shown inhibits virus attachment, neutralizes infectivity and blocks apoptosis induced by infectious virus (Tyler et al., 1996) , did not block apoptosis induced in the indicator cells by supernatant transfer from reovirus-infected cancer cells. This antibody did inhibit viral growth and virus-induced apoptosis in reovirus-infected cancer cells (data not shown) indicating that the apoptotic eects of infected cancer cell supernatants are not due to the presence of infectious virus.
Reovirus synergistically augments TRAIL-mediated apoptosis in infected cancer cells
Reovirus infection sensitizes HEK293 cells to TRAILinduced apoptosis. We next wished to determine whether reovirus infection also sensitized cancer cells to TRAIL-induced apoptosis, and if so, whether this sensitization was speci®c for TRAIL-induced apoptosis or whether it also occurred with other death-receptor associated ligands. ZR75-1 and H157 cells, which were the cancer cell lines that showed the least susceptibility to TRAIL (200 ng/ml)-induced apoptosis ( Figure 1A ), were infected with reovirus (MOI 10). After 24 h infected cells were treated with a low dose of TRAIL (20 ng/ml) and apoptosis assays were performed after a further 24 h. In H157 and ZR75-1 cells neither low doses of TRAIL (20 ng/ml) or reovirus (MOI 10) alone induce signi®cant apoptosis compared to untreated cells ( Figure 3A) . However, when cells were infected with reovirus and were then treated with TRAIL the number of apoptotic cells was signi®cantly increased (P50.05) when compared to uninfected cells, or to cells treated with either TRAIL or reovirus alone. The increase in apoptosis induced by a combination of reovirus-infection and TRAIL treatment was synergistic rather than additive, compared to that seen with either agent alone, and the amount of apoptosis seen with TRAIL and reovirus together was signi®cantly dierent from the sum of reo-and TRAIL-induced apoptosis when each was administered separately. To con®rm that cell death resulting from a combination of reovirus-infection and TRAIL treatment was due to apoptosis we also showed that a combination of reovirus and TRAIL, but not the same doses of reovirus or TRAIL alone, produced oligosomal DNA fragmentation, also known as`DNA laddering' ( Figure  3B ).
Reovirus infection also signi®cantly (P50.05) augmented apoptosis induced in ZR75-1 and H157 cells by an activating Fas antibody (0.025 mg/ml) compared to cells treated with either the antibody or reovirus alone ( Figure 3C ). This augmentation was additive rather than synergistic and the amount of apoptosis seen with a combination of antibody and reovirus was not signi®cantly dierent from the sum of reo-and antibody-induced apoptosis when each was administered separately. This indicates that the synergistic sensitization of reovirus-infected cells to TRAIL is a speci®c event.
Reovirus does not augment doxorubicin-induced apoptosis
Doxorubicin is a cancer therapeutic agent that augments TRAIL induced apoptosis. Doxorubicin induces apoptosis in treated cells, as demonstrated by caspase 3 activation (Keane et al., 1999) but this apoptosis does not occur through cellular death receptors. We wondered whether reovirus infection might enhance doxorubicin-induced, as well as TRAILinduced, apoptosis. ZR75-1 cells, which are sensitized to TRAIL-induced apoptosis following reovirus infection, were treated with dierent concentrations of doxorubicin 24 h following reovirus or mock-infection and were assayed for the presence of apoptotic nuclear morphology after a further 24 h. Figure 4A shows that doxorubicin concentrations of below 0.5 mM did not induce apoptosis in either infected or uninfected ZR75-1 cells, concentrations of 1 ± 2 mM induced around 60 ± 80% apoptosis in either infected or uninfected cells and doxorubicin concentrations of 3 mM killed 100% of treated cells. There was no signi®cant dierence in doxorubicin-induced apoptosis in reovirus-infected, compared to uninfected cells, at any of the doxorubicin concentrations tested. We selected concentrations of 0.25 and 0.5 mM doxorubicin to further investigate the eect of reovirus-infection on doxorubicin-induced apoptosis. We also investigated the eect of TRAIL (20 ng/ml) on doxorubicin-induced apoptosis. Cells were infected with reovirus (MOI 10), or were mockinfected. Twenty-four hours later cells were treated with doxorubicin (0.25 and 0.5 mM) and/or TRAIL (20 ng/ml) and were assayed for apoptosis after a further 24 h. Figure 4B shows that reovirus-infection does not signi®cantly augment 0.25 mM doxorubicininduced apoptosis in ZR75-1 cells, compared to cells treated with 0.25 mM doxorubicin alone (similar results were obtained with 0.5 mM doxorubicin, results not shown). As shown above ZR75-1 cells were sensitized to TRAIL-induced apoptosis following reovirus infection. Doxorubicin also augmented TRAIL-induced apoptosis in ZR75-1 cells. Similar results were obtained in H157 cells (data not shown). These results suggest that reovirus infection does not sensitize cells to doxorubicin-induced apoptosis and supports our ®nd-ing that the sensitization of reovirus-infected cells to TRAIL is a speci®c event.
Reovirus infection does not alter the expression of TRAIL receptors in cancer cell lines
Having shown that reovirus speci®cally augments TRAIL-induced apoptosis we wished to determine the mechanism by which this occurs. The sensitivity of cells to TRAIL-induced apoptosis is dependent, in part on the expression of the apoptosis-inducing receptors DR4 and DR5. We therefore assayed TRAIL receptor expression in reovirus-infected cancer cells to determine whether reovirus sensitizes cells to TRAIL-induced apoptosis by altering TRAIL receptor expression in infected cells. Gene expression was analysed in mockand reovirus-infected lung and cervical cancer cells by semi-quantitative RTPCR, 12 and 24 h post infection ( Figure 5A ) and by FACS analysis of cell surface receptor expression in breast cancer cells, 24 h post infection ( Figure 5B ). DR5 mRNA was expressed in all the cell lines tested and did not alter following infection with reovirus. DR5 cell surface expression was also unaltered following infection with reovirus and FACS analysis of DR5 staining in mock-infected and reovirus-infected cells produced identical traces ( Figure  5B ). The expression of DR4 mRNA is dependent on cell type. HeLa and H157 cells express DR4 mRNA whereas A549 cells express very little DR4 mRNA. However, there is no change in the expression of either DR4 mRNA (Figure 5A ), or of cell surface DR4 ( Figure 5B ), in cells following reovirus infection. The expression of neither DcR-1 nor DcR-2 mRNA was altered by reovirus infection (data not shown).
Taken together these results indicate that reovirus infection does not alter TRAIL-receptor expression and that changes in receptor expression do not Reovirus-induced sensitization to TRAIL is associated with an increase in the activity of caspase 8
Since both TRAIL (Muhlenbeck et al., 1998) and reovirus-induced (Kominsky et al., submitted) apoptosis are associated with the activation of caspase 8 we wished to determine whether caspase 8 was involved in reovirusinduced sensitization of cells to TRAIL. As expected high doses of TRAIL alone (200 ng/ml) and of reovirus alone (MOI 100) activated caspase 8 in H157 cells, as determined by the cleavage of pro-caspase 8 ( Figure 6A ). We next looked to see if the activity of caspase 8 was increased in reovirus-infected, TRAIL-treated cells compared to cells treated with TRAIL alone. We tested the ability of increasing doses of reovirus (MOI 0, 10, 100) to augment TRAIL-induced caspase 8 activation in cells treated with low levels of TRAIL (20 ng/ml), that are insucient to activate caspase 8 by themselves. H157 cells were infected with reovirus and 12 h following infection were treated with TRAIL (20 ng/ml). Cells were harvested 0 and 24 h later and extracts were run on tricine gels and were probed with antibody directed against pro-caspase 8 ( Figure 6B ). Pro-caspase 8 was not cleaved in the presence of low doses (20 ng/ml) of TRAIL alone but was cleaved in the presence of TRAIL (20 ng/ml) and reovirus, in a MOI-dependent manner ( Figure 6B ). These results indicate that reovirus augments caspase 8 activation in TRAIL treated cells.
Having shown that reovirus-induced sensitization to TRAIL is associated with an increase in the activation of caspase 8 we next wanted to see if reovirus-induced sensitization of cells was blocked using IETD-fmk, a For the detection of caspase 8 activation extracts were run on tricine gels and were probed with antibody directed against procaspase 8. All samples were standardized for protein concentration using actin (not shown). (C) ZR75-1 cells were either mockinfected or infected with reovirus (MOI 10). After 24 h cells were treated with TRAIL (20 ng/ml), or were left untreated, in the presence or absence of IETD-fmk (50 mM). The graph shows the mean per cent of apoptotic nuclei in cells from three separate experiments. Error bars represent standard errors of the mean peptide capable of inhibiting caspase 8 activity. The presence of IETD-fmk (50 mM) signi®cantly (P50.05) reduced the ability of reovirus to sensitize cells to TRAIL in both H157 (data not shown) and ZR75-1 cells ( Figure 6C ), providing further evidence that reovirus-induced sensitization of cells to TRAIL involves a caspase 8-dependent pathway.
Reovirus-induced sensitization to TRAIL is associated with an increase in the activity of effector caspases
Having shown that reovirus-induced sensitization to TRAIL is associated with an increase in the activation of caspase 8 we next looked to see whether there was an increase in the activation of downstream, eector, caspases in reovirus-infected, TRAIL-treated cells compared to cells treated with TRAIL alone. The eector caspases that have been shown to operate downstream of caspase 8 are caspases 3 and 7. We thus examined the cleavage of the caspase 3 and 7 substrate PARP, as a monitor of activation of eector caspases. Cells were infected with reovirus (MOI 0, 10, 100) and were treated with TRAIL (20 ng/ml) 12 h following infection. After a further 3 h cells were harvested and probed with an antibody directed against PARP. Figure 7 shows the disappearance of PARP (corresponding to its cleavage) in the cell lysates, following treatment with TRAIL. This was enhanced when the cells were ®rst infected with reovirus, indicating that reovirus infection increases the amount of eector caspase activation in TRAILtreated cells.
Discussion
Our results demonstrate that reovirus induces apoptosis in a variety of cell lines derived from human cancers. Apoptosis was determined by the presence of apoptotic nuclear morphology and the increase in the activity of caspase 3 in reovirus-infected cells. Although the 2 ± 3-fold increase in the activity of caspase 3 that we obtained following reovirus infection is fairly modest it is typical of results obtained in other cell lines (Dr D Kominski, personal communication) . It is unclear to us why reovirus produces such a low level of caspase 3 activity in infected cells. Possibly, a low level of activation over a long period of time is sucient for reovirus-induced apoptosis. Alternatively reovirus may induce increased levels of additional eector caspases, which contribute to apoptosis in reovirus-infected cells. Certainly, the cancer cell lines that we have used show a much higher caspase 3 activity (20+fold) following TRAIL treatment (results not shown).
Similar to a recent report that showed that cells that were resistant to chemotherapy were also resistant to TRAIL (Cuello et al., 2001) , there is a signi®cant correlation between the sensitivity of the cancer cell lines to apoptosis induced by reovirus and TRAIL. Further, reovirus-induced apoptosis is blocked both by the presence of soluble TRAIL receptor Fc:DR5 and by the over-expression of DcR-1. These results indicate that reovirus-induced apoptosis in cancer cells is mediated by TRAIL. Similar to our results in HEK293 cells we now show that TRAIL is released from all but one of the cancer cell lines tested following infection with reovirus.
Reovirus-induced oncolysis has been previously described . Our current results indicate that oncolysis results from apoptosis and that TRAIL plays an essential role in this process. Other viruses may also utilize the TRAIL apoptotic pathway. For example, HIV infection increases the expression of TRAIL and sensitizes T-cells to TRAIL-mediated apoptosis (Jeremias et al., 1998) . Modulation of TRAIL and TRAIL receptor expression also occurs following infection with human cytomegalovirus (Sedger et al., 1999) and Theiler's murine encephalomyelitis virus has been shown to induce apoptosis through a mechanism involving TRAIL (Jelachich and Lipton, 2001) . Previous studies have suggested that other members of the TNFR death receptor superfamily may also be involved in virus-induced apoptosis. Alteration of the cell surface expression of Fas may be involved in virus-induced, or viral regulation of, apoptosis in cells infected with in¯uenza virus (Takizawa et al., 1993 (Takizawa et al., , 1995 , herpes simplex virus type 2 (Sieg et al., 1996) , bovine herpesvirus 4 (BHV 4) (Wang et al., 1997) , adenovirus (Tollefson et al., 1998) and human immunode®ciency virus type 1 (HIV 1) (Conaldi et al., 1998; Kaplan and Sieg, 1998) . Similarly, apoptosis induced by Hepatitis B (Su and Schneider, 1997), HIV-1 (Herbein et al., 1998) , BHV 4 (Wang et al., 1997) parvovirus H-1 (Rayet et al., 1998) and Theiler's murine encephalomyelitis virus (Jelachich and Lipton, 2001) , may involve the TNFR signaling pathway.
In addition to its capacity to kill cancer cells by apoptosis, we show that reovirus infection also sensitizes cancer cells to TRAIL induced apoptosis in a synergistic manner. H157 and ZR75-1 cells, which are relatively resistant to TRAIL-induced killing, became much more susceptible following infection with reovirus. Reovirus-induced sensitization of cells is speci®c for TRAIL and reovirus does not synergistically sensitize cells to Fas-mediated apoptosis (another death receptor apoptotic pathway) or to apoptosis Figure 7 Reovirus infection increases the activation of caspase 3 in TRAIL treated cells. H157 cells were infected with reovirus (MOI 0, 10, 100). Twelve hours following infection cells were treated with low dose TRAIL (20 ng/ml) and were harvested at various times post treatment. Extracts were probed with antibody directed against the caspase 3 substrate, PARP. Samples were standardized for protein concentration using actin (not shown) induced by doxorubicin (a non-death receptor apoptotic agent).
We next investigated the mechanism by which reovirus sensitizes cells to TRAIL. The level of TRAIL receptor expression at the cell surface does not change following infection with reovirus indicating that upregulation of TRAIL receptor is not the mechanism by which reovirus sensitizes cells to TRAIL. The activation of caspase 8 however, is increased in cells following a combination of reovirus-infection and TRAIL-treatment, compared to uninfected cells or to cells treated with TRAIL or reovirus alone. Caspase 8, an initiator caspase, activates the eector caspases 3 and 7 and we show that there is increased cleavage of the eector caspase substrate, PARP, in reovirusinfected, TRAIL-treated cells, compared to cells treated with TRAIL alone. The role of caspase 8 in reovirus-induced sensitization of cells to TRAIL is supported by our demonstration that the peptide IETD-fmk, which inhibits caspase 8 activity and blocks both TRAIL-induced (Yu et al., 2000) and reovirusinduced apoptosis, blocks reovirus-induced sensitization to TRAIL. The expression of DN-FADD, which blocks the activation of caspase 8, also blocks reovirus-induced sensitization to TRAIL in HEK293 cells (results not shown).
The involvement of caspase 8 in reovirus-induced sensitization of cells to TRAIL suggests that reovirus sensitizes cells to TRAIL-induced apoptosis by augmenting the TRAIL pathway of apoptosis rather than by activating a second apoptotic pathway. This suggests that the mechanism by which reovirus sensitizes cells to TRAIL-induced apoptosis diers from the recently identi®ed mitochondrial-dependent pathway by which sodium nitroprusside (Lee et al., 2001 ) and ionizing radiation (Belka et al., 2001) enhance TRAIL-induced apoptosis. The release of TRAIL from reovirus-infected cells may contribute to the increased activation of caspase 8 in reovirusinfected, TRAIL treated cells. However, ZR75-1 cells, which do not release TRAIL following reovirus infection, are sensitized to TRAIL-induced apoptosis following infection with reovirus. This implies that TRAIL release cannot be the only mechanism for the increased levels of caspase 8 activation in reovirusinfected, TRAIL-treated cells.
The cleavage of procaspase 8 to its active counterpart is required for TRAIL-induced apoptosis. The caspase 8 homologue, FLICE inhibitory protein (cFLIP), promotes cell survival by blocking this reaction and its has been shown that inducers of the transcription factor NF-kB can upregulate cFLIP (Kreuz et al., 2001) . Although reovirus induces the activation of NF-kB (Connolly et al., 2000) similar levels of expression of the cellular inhibitor of caspase 8 activation (FLIP) were observed in reovirus-infected, TRAIL-treated cells compared to that in cells treated with TRAIL alone (results not shown) indicating that the increased activation of caspase 8 is not due to a reduction in FLIP-mediated inhibition of caspase 8.
These results show that reovirus-induced oncolysis of cancer cells occurs through TRAIL-mediated apoptosis and suggest that reovirus-infection is a useful model for investigations of TRAIL-induced apoptosis in cancer cells. Similar to the eects of genotoxins , reovirus sensitizes cells to TRAIL induced apoptosis. Our results show that reovirus-induced sensitization of cells to TRAIL is inhibited by IETDfmk and is associated with the activation of caspase 8. Further studies of this phenomenon may suggest new strategies to enhance the killing of cancer cells by TRAIL.
Materials and methods
Cells and virus
HEK293 cells (ATCC CRL1573) were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 100 U/ml each of penicillin and streptomycin and containing 10% fetal bovine serum. HeLa cells (ATCC CCL2) were grown in Eagle's minimal essential medium (MEM) supplemented with 2.4 mM L-glutamine, non-essential amino acids, 60 U/ml each of penicillin and streptomycin and containing 10% fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA). HeLa cells were used as indicator cells in the supernatant transfer experiments. The lung cancer cell lines (A549 and H157) and breast cancer cell lines (MDA-MB231 and ZR75-1) were obtained from the University of Colorado Cancer Center. Reovirus (Type 3 Abney, T3A) is a laboratory stock, which has been plaque puri®ed and passaged (twice) in L929 (ATCC CCL1) cells to generate working stocks (Tyler et al., 1996) . Virus growth was determined by plaque assay as previously described (Tyler et al., 1985) .
Apoptosis assays and reagents
Determination of Apoptotic Nuclear morphology: 48 h after infection with reovirus cells were harvested and stained with acridine orange, for determination of nuclear morphology and ethidium bromide, to distinguish cell viability, at a ®nal concentration of 1 mg/ml each (Duke and Cohen, 1992) . Following staining, cells were examined by epi¯uorescence microscopy (Nikon Labophot-2: B-2A ®lter, excitation, 450 ± 490 nm; barrier, 520 nm; dichroic mirror, 505 nm). The percentage of cells containing condensed nuclei and/or marginated chromatin in a population of 100 cells was recorded. The speci®city of this assay for detecting apoptotic cells has been previously established in reovirus-infected cells using DNA laddering techniques and electron microscopy (Tyler et al., 1995) . DNA laddering: Cells (5610 6 ) were removed from culture¯asks and resuspended in 2 ml digestion buer (0.1 M NaCl, 10 mM Tris pH 8, 25 mM EDTA, 0.5% SDS and 0.3 mg/ml proteinase K). Following overnight incubation at 508C the suspension was extracted with phenol/chloroform and then chloroform. DNA was then treated with RNase (20 mg/ml) for 1 h at 378C, followed by further extraction with phenol/chloroform and then chloroform. DNA was then puri®ed by overnight ethanol precipitation (1/2 volumes 7.5 M NH 4 -acetate and three volumes cold 100% ethanol) at 7208C. The precipitate was spun down at 9000 r.p.m. for 30 min, washed in ethanol (85%), dried and resuspended in 200 ml TE. DNA was then run on a 1.5% agarose gel, stained with ethidium bromide and visualized using a Fluor-S MultiImager and Quantity One software (BioRad, Hercules, CA, USA). For the sensitization experiments cells were infected with reovirus at a multiplicity of infection (MOI) of 10. After 24 h cells were treated with 20 ng/ml TRAIL (Upstate Biotechnology, Lake Placid, NY, USA), 0.025 mg/ml of an activating Fas antibody (Upstate Biotechnology) or 0.25/0.5 mM doxorubicin (Sigma, St. Louis, MO, USA) and apoptosis assays were performed after a further 24 h. Soluble death receptors Fc:DR5 and Fc:TNFR were obtained from Alexis Corporation (Pittsburgh, PA, USA). The cell permeable caspase inhibitor IETD-fmk was obtained from Clontech (Palo Alto, CA, USA). Anti-reovirus antibody is a neutralizing polyclonal anti-reovirus antisera, that neutralizes infectivity and blocks apoptosis induced by infectious virus (Tyler et al., 1995) .
Caspase 3 activation assays
Caspase 3 activation assays were performed using a kit obtained from Clontech. Experiments were performed using 1610 6 cells/time point. Cells were centrifuged at 200 g for 10 min, supernatants were removed and cell pellets were frozen at 7708C until all time points were collected. Assays were performed in 96 well plates and analysed using ā uoresent plate reader (CytoFluor 4000, PerSeptive Biosystems, Farmington, MA, USA). Cleavage of DEVD-AFC, a synthetic caspase-3 substrate, was used to measure caspase 3 activation in reovirus-infected cells. Cleavage after the second Asp residue produces free AFC that can be detected using ā uorescent plate reader. The amount of¯uorescence detected is directly proportional to the amount of caspase 3 activity.
Western blot analysis
Following infection with reovirus, cells were pelleted by centrifugation, washed twice with ice-cold phosphate-buered saline and lysed by sonication in 200 ml of a buer containing 15 mM Tris, pH 7.5, 2 mM EDTA, 10 mM EGTA, 20% glycerol, 0.1% NP-40, 50 mM mercaptoethanol, 100 mg/ml leupeptin, 2 mg/ml aprotinin, 40 mM Z-D-DCB, and 1 mM PMSF. The lysates were then cleared by centrifugation at 16 000 g for 5 min, normalized for protein amount, mixed 1 : 1 with SDS sample buer (100 mM Tris, pH 6.8, 2% SDS, 300 mM mercaptoethanol, 30% glycerol, and 5% pyronine Y), boiled for 5 min and stored at 7708C. Proteins were electrophoresed by SDS ± PAGE (10% gels) and probed with anti-caspase 8 (B9-2, Pharmingen, San Diego, CA, USA) and anti-PARP (9542, Cell Signaling Technologies, CA, USA) antibodies. All lysates were standardized for protein concentration with antibodies directed against actin (CP01, Oncogene, Cambridge, MA, USA).
RTPCR
Cells were seeded (5610 6 ) and were infected with reovirus (MOI 100). At 24 h post infection cells were washed in PBS and were harvested directly into RNA lysis buer. Total cellular RNA was prepared using RNeasy minicolumns (Qiagen, Valencia, CA, USA). Two mg of RNA was used as template for ®rst strand synthesis using a pre-ampli®cation system (Life Technologies, Grand Island, NY, USA). Semiquantitative RTPCR ampli®cation reactions speci®c to DR4, DR5, DcR-1 and DcR-2 were performed . Actin primers were used as controls.
Flow cytometry
Cells were removed from tissue culture¯asks by repeat pipetting or gentle tapping and were suspended in PBS (10 5 cells/ml). Cells were pelleted by centrifugation (2000 r.p.m. for 2 min, then maximum pulse for 10 s) and were then resuspended in 500 ml wash buer 1 (PBS containing 2% fetal calf serum and 0.02% sodium azide). Cells were pelleted as above and resuspended in 500 ml staining solution (PBS containing 5% fetal calf serum and 0.02% sodium azide) for 5 min at room temperature. Cells were then pelleted as before and resuspended in 50 ml staining solution, alone for negative control and with primary antibody (2 ml/ml) for experimental samples. Cells were then incubated at 48C in the dark for 30 min before being washed twice in wash buer 1 (centrifuging as described above). After a ®nal centrifugation step cells were resuspended in staining solution and secondary antibody conjugated to¯uorophore (anti-mouse IgG1-FITC) and were incubated at 48C in the dark for 30 min. Cells were then pelleted (as above) twice and resuspended ®rst in wash buer 1 and then in wash buer 2 (PBS containing 0.02% sodium azide). Cells were then centrifuged (as above), ®xed in 500 ml 1% paraformaldehyde and analysed by¯ow cytometry.
For these experiments monoclonal antibodies against human DR4 (huTR1-M271) and DR5 (huTRAILR2-M413) were used (Immunex Corporation, Seattle, WA, USA).
